Vistagen develops nasal spray medicine candidates for conditions such as social anxiety disorder and depression. VTGN reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Seasonality
How VTGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.
Whale Options Flow
90DNo whale options trades in VTGN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VTGN is in one of them and how their past VTGN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VTGN in an article yet. Here's the latest on the wider market.
About Vistagen Therapeutics
Vistagen is a pharmaceutical company based in South San Francisco, California, that is developing medicines for conditions including social anxiety disorder, depression, menopausal hot flashes, and cancer cachexia. Its candidates are nasal sprays designed to act on nerve receptors in the nose, with the aim of working without being absorbed into the bloodstream. The company has no approved products yet, and its candidates are being tested in clinical trials with patients.
- Headquarters
- South San Francisco, CA